1
|
Wang Y, Zhang Z, Piao C, Huang Y, Zhang Y, Zhang C, Lu YJ, Liu D. LDS-CNN: a deep learning framework for drug-target interactions prediction based on large-scale drug screening. Health Inf Sci Syst 2023; 11:42. [PMID: 37667773 PMCID: PMC10475000 DOI: 10.1007/s13755-023-00243-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Accepted: 08/14/2023] [Indexed: 09/06/2023] Open
Abstract
Background Drug-target interaction (DTI) is a vital drug design strategy that plays a significant role in many processes of complex diseases and cellular events. In the face of challenges such as extensive protein data and experimental costs, it is suggested to apply bioinformatics approaches to exploit potential interactions to design new targeted medications. Different data and interaction types bring difficulties to study involving incompatible and heterology formats. The analysis of drug-target interactions in a comprehensive and unified model is a significant challenge. Method Here, we propose a general method for predicting interactions between small-molecule drugs and protein targets, Large-scale Drug target Screening Convolutional Neural Network (LDS-CNN), which used unified encoding to achieve the calculation of the different data formats in an integrated model to realize feature abstraction and potential object prediction. Result On 898,412 interaction data involving 1683 small-molecule compounds and 14,350 human proteins from 8.8 billion records, the proposed method achieved an area under the curve (AUC) of 0.96, an area under the precision-recall curve (AUPRC) of 0.95, and an accuracy of 90.13%. The experimental results illustrated that the proposed method attained high accuracy on the test set, indicating its high predictive ability in drug-target interaction prediction. LDS-CNN is effective for the prediction of large-scale datasets and datasets composed of data with different formats. Conclusion In this study, we propose a DTI prediction method to solve the problems of unified encoding of large-scale data in multiple formats. It provides a feasible way to efficiently abstract the features among different types of drug-related data, thus reducing experimental costs and time consumption. The proposed method can be used to identify potential drug targets and candidates for the treatment of complex diseases. This work provides a reference for DTI to process large-scale data and different formats with deep learning methods and provides certain suggestions for future research.
Collapse
Affiliation(s)
- Yang Wang
- School of Computer Science and Technology, Guangdong University of Technology, Guangzhou, 510006 China
| | - Zuxian Zhang
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006 China
| | - Chenghong Piao
- The First Affiliated Hospital of Ningbo University, Ningbo, 315010 China
| | - Ying Huang
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006 China
| | - Yihan Zhang
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006 China
| | - Chi Zhang
- Shanghai Institute of Biological Products, Shanghai, 201403 China
| | - Yu-Jing Lu
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006 China
- Smart Medical Innovation Technology Center, Guangdong University of Technology, Guangzhou, 510006 China
| | - Dongning Liu
- School of Computer Science and Technology, Guangdong University of Technology, Guangzhou, 510006 China
| |
Collapse
|
2
|
Kusuma WA, Fadli A, Fatriani R, Sofyantoro F, Yudha DS, Lischer K, Nuringtyas TR, Putri WA, Purwestri YA, Swasono RT. Prediction of the interaction between Calloselasma rhodostoma venom-derived peptides and cancer-associated hub proteins: A computational study. Heliyon 2023; 9:e21149. [PMID: 37954374 PMCID: PMC10637925 DOI: 10.1016/j.heliyon.2023.e21149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 09/04/2023] [Accepted: 10/17/2023] [Indexed: 11/14/2023] Open
Abstract
The use of peptide drugs to treat cancer is gaining popularity because of their efficacy, fewer side effects, and several advantages over other properties. Identifying the peptides that interact with cancer proteins is crucial in drug discovery. Several approaches related to predicting peptide-protein interactions have been conducted. However, problems arise due to the high costs of resources and time and the smaller number of studies. This study predicts peptide-protein interactions using Random Forest, XGBoost, and SAE-DNN. Feature extraction is also performed on proteins and peptides using intrinsic disorder, amino acid sequences, physicochemical properties, position-specific assessment matrices, amino acid composition, and dipeptide composition. Results show that all algorithms perform equally well in predicting interactions between peptides derived from venoms and target proteins associated with cancer. However, XGBoost produces the best results with accuracy, precision, and area under the receiver operating characteristic curve of 0.859, 0.663, and 0.697, respectively. The enrichment analysis revealed that peptides from the Calloselasma rhodostoma venom targeted several proteins (ESR1, GOPC, and BRD4) related to cancer.
Collapse
Affiliation(s)
- Wisnu Ananta Kusuma
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, 16680, Indonesia
- Tropical Biopharmaca Research Center, IPB University, Bogor, 16128, Indonesia
| | - Aulia Fadli
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, 16680, Indonesia
| | - Rizka Fatriani
- Tropical Biopharmaca Research Center, IPB University, Bogor, 16128, Indonesia
| | - Fajar Sofyantoro
- Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
| | - Donan Satria Yudha
- Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
| | - Kenny Lischer
- Faculty of Engineering, University of Indonesia, Jakarta, 16424, Indonesia
| | - Tri Rini Nuringtyas
- Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
- Research Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
| | | | - Yekti Asih Purwestri
- Faculty of Biology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
- Research Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
| | - Respati Tri Swasono
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
| |
Collapse
|
3
|
Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals (Basel) 2023; 16:1259. [PMID: 37765069 PMCID: PMC10537003 DOI: 10.3390/ph16091259] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 08/24/2023] [Accepted: 09/04/2023] [Indexed: 09/29/2023] Open
Abstract
Artificial intelligence (AI) has permeated various sectors, including the pharmaceutical industry and research, where it has been utilized to efficiently identify new chemical entities with desirable properties. The application of AI algorithms to drug discovery presents both remarkable opportunities and challenges. This review article focuses on the transformative role of AI in medicinal chemistry. We delve into the applications of machine learning and deep learning techniques in drug screening and design, discussing their potential to expedite the early drug discovery process. In particular, we provide a comprehensive overview of the use of AI algorithms in predicting protein structures, drug-target interactions, and molecular properties such as drug toxicity. While AI has accelerated the drug discovery process, data quality issues and technological constraints remain challenges. Nonetheless, new relationships and methods have been unveiled, demonstrating AI's expanding potential in predicting and understanding drug interactions and properties. For its full potential to be realized, interdisciplinary collaboration is essential. This review underscores AI's growing influence on the future trajectory of medicinal chemistry and stresses the importance of ongoing synergies between computational and domain experts.
Collapse
Affiliation(s)
| | | | | | | | - Yoonji Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea
| |
Collapse
|
4
|
Sinha K, Ghosh N, Sil PC. A Review on the Recent Applications of Deep Learning in Predictive Drug Toxicological Studies. Chem Res Toxicol 2023; 36:1174-1205. [PMID: 37561655 DOI: 10.1021/acs.chemrestox.2c00375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/12/2023]
Abstract
Drug toxicity prediction is an important step in ensuring patient safety during drug design studies. While traditional preclinical studies have historically relied on animal models to evaluate toxicity, recent advances in deep-learning approaches have shown great promise in advancing drug safety science and reducing animal use in preclinical studies. However, deep-learning-based approaches also face challenges in handling large biological data sets, model interpretability, and regulatory acceptance. In this review, we provide an overview of recent developments in deep-learning-based approaches for predicting drug toxicity, highlighting their potential advantages over traditional methods and the need to address their limitations. Deep-learning models have demonstrated excellent performance in predicting toxicity outcomes from various data sources such as chemical structures, genomic data, and high-throughput screening assays. The potential of deep learning for automated feature engineering is also discussed. This review emphasizes the need to address ethical concerns related to the use of deep learning in drug toxicity studies, including the reduction of animal use and ensuring regulatory acceptance. Furthermore, emerging applications of deep learning in drug toxicity prediction, such as predicting drug-drug interactions and toxicity in rare subpopulations, are highlighted. The integration of deep-learning-based approaches with traditional methods is discussed as a way to develop more reliable and efficient predictive models for drug safety assessment, paving the way for safer and more effective drug discovery and development. Overall, this review highlights the critical role of deep learning in predictive toxicology and drug safety evaluation, emphasizing the need for continued research and development in this rapidly evolving field. By addressing the limitations of traditional methods, leveraging the potential of deep learning for automated feature engineering, and addressing ethical concerns, deep-learning-based approaches have the potential to revolutionize drug toxicity prediction and improve patient safety in drug discovery and development.
Collapse
Affiliation(s)
- Krishnendu Sinha
- Department of Zoology, Jhargram Raj College, Jhargram 721507, West Bengal, India
| | - Nabanita Ghosh
- Department of Zoology, Maulana Azad College, Kolkata 700013, West Bengal, India
| | - Parames C Sil
- Division of Molecular Medicine, Bose Institute, Kolkata 700054, West Bengal, India
| |
Collapse
|
5
|
Zabihian A, Sayyad FZ, Hashemi SM, Shami Tanha R, Hooshmand M, Gharaghani S. DEDTI versus IEDTI: efficient and predictive models of drug-target interactions. Sci Rep 2023; 13:9238. [PMID: 37286613 DOI: 10.1038/s41598-023-36438-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 06/03/2023] [Indexed: 06/09/2023] Open
Abstract
Drug repurposing is an active area of research that aims to decrease the cost and time of drug development. Most of those efforts are primarily concerned with the prediction of drug-target interactions. Many evaluation models, from matrix factorization to more cutting-edge deep neural networks, have come to the scene to identify such relations. Some predictive models are devoted to the prediction's quality, and others are devoted to the efficiency of the predictive models, e.g., embedding generation. In this work, we propose new representations of drugs and targets useful for more prediction and analysis. Using these representations, we propose two inductive, deep network models of IEDTI and DEDTI for drug-target interaction prediction. Both of them use the accumulation of new representations. The IEDTI takes advantage of triplet and maps the input accumulated similarity features into meaningful embedding corresponding vectors. Then, it applies a deep predictive model to each drug-target pair to evaluate their interaction. The DEDTI directly uses the accumulated similarity feature vectors of drugs and targets and applies a predictive model on each pair to identify their interactions. We have done a comprehensive simulation on the DTINet dataset as well as gold standard datasets, and the results show that DEDTI outperforms IEDTI and the state-of-the-art models. In addition, we conduct a docking study on new predicted interactions between two drug-target pairs, and the results confirm acceptable drug-target binding affinity between both predicted pairs.
Collapse
Affiliation(s)
- Arash Zabihian
- Laboratory of Bioinformatics and Drug Design (LBD), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
- Department of Bioinformatics, Kish International Campus, University of Tehran, Kish, Iran
| | - Faeze Zakaryapour Sayyad
- Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran
| | - Seyyed Morteza Hashemi
- Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran
| | - Reza Shami Tanha
- Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran
| | - Mohsen Hooshmand
- Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran.
| | - Sajjad Gharaghani
- Laboratory of Bioinformatics and Drug Design (LBD), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
| |
Collapse
|
6
|
Abbasi Mesrabadi H, Faez K, Pirgazi J. Drug-target interaction prediction based on protein features, using wrapper feature selection. Sci Rep 2023; 13:3594. [PMID: 36869062 PMCID: PMC9984486 DOI: 10.1038/s41598-023-30026-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 02/14/2023] [Indexed: 03/05/2023] Open
Abstract
Drug-target interaction prediction is a vital stage in drug development, involving lots of methods. Experimental methods that identify these relationships on the basis of clinical remedies are time-taking, costly, laborious, and complex introducing a lot of challenges. One group of new methods is called computational methods. The development of new computational methods which are more accurate can be preferable to experimental methods, in terms of total cost and time. In this paper, a new computational model to predict drug-target interaction (DTI), consisting of three phases, including feature extraction, feature selection, and classification is proposed. In feature extraction phase, different features such as EAAC, PSSM and etc. would be extracted from sequence of proteins and fingerprint features from drugs. These extracted features would then be combined. In the next step, one of the wrapper feature selection methods named IWSSR, due to the large amount of extracted data, is applied. The selected features are then given to rotation forest classification, to have a more efficient prediction. Actually, the innovation of our work is that we extract different features; and then select features by the use of IWSSR. The accuracy of the rotation forest classifier based on tenfold on the golden standard datasets (enzyme, ion channels, G-protein-coupled receptors, nuclear receptors) is as follows: 98.12, 98.07, 96.82, and 95.64. The results of experiments indicate that the proposed model has an acceptable rate in DTI prediction and is compatible with the proposed methods in other papers.
Collapse
Affiliation(s)
- Hengame Abbasi Mesrabadi
- Faculty of Computer and Information Technology Engineering, Qazvin Branch, Islamic Azad University, Qazvin, Iran
| | - Karim Faez
- Department of Electrical Engineering, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran.
| | - Jamshid Pirgazi
- Department of Computer Engineering, University of Science and Technology of Mazandaran, Behshahr, Iran
| |
Collapse
|
7
|
DRaW: prediction of COVID-19 antivirals by deep learning-an objection on using matrix factorization. BMC Bioinformatics 2023; 24:52. [PMID: 36793010 PMCID: PMC9931173 DOI: 10.1186/s12859-023-05181-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 02/09/2023] [Indexed: 02/17/2023] Open
Abstract
BACKGROUND Due to the high resource consumption of introducing a new drug, drug repurposing plays an essential role in drug discovery. To do this, researchers examine the current drug-target interaction (DTI) to predict new interactions for the approved drugs. Matrix factorization methods have much attention and utilization in DTIs. However, they suffer from some drawbacks. METHODS We explain why matrix factorization is not the best for DTI prediction. Then, we propose a deep learning model (DRaW) to predict DTIs without having input data leakage. We compare our model with several matrix factorization methods and a deep model on three COVID-19 datasets. In addition, to ensure the validation of DRaW, we evaluate it on benchmark datasets. Furthermore, as an external validation, we conduct a docking study on the COVID-19 recommended drugs. RESULTS In all cases, the results confirm that DRaW outperforms matrix factorization and deep models. The docking results approve the top-ranked recommended drugs for COVID-19. CONCLUSIONS In this paper, we show that it may not be the best choice to use matrix factorization in the DTI prediction. Matrix factorization methods suffer from some intrinsic issues, e.g., sparsity in the domain of bioinformatics applications and fixed-unchanged size of the matrix-related paradigm. Therefore, we propose an alternative method (DRaW) that uses feature vectors rather than matrix factorization and demonstrates better performance than other famous methods on three COVID-19 and four benchmark datasets.
Collapse
|
8
|
Peng Y, Zhao S, Zeng Z, Hu X, Yin Z. LGBMDF: A cascade forest framework with LightGBM for predicting drug-target interactions. Front Microbiol 2023; 13:1092467. [PMID: 36687573 PMCID: PMC9849804 DOI: 10.3389/fmicb.2022.1092467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 12/07/2022] [Indexed: 01/07/2023] Open
Abstract
Prediction of drug-target interactions (DTIs) plays an important role in drug development. However, traditional laboratory methods to determine DTIs require a lot of time and capital costs. In recent years, many studies have shown that using machine learning methods to predict DTIs can speed up the drug development process and reduce capital costs. An excellent DTI prediction method should have both high prediction accuracy and low computational cost. In this study, we noticed that the previous research based on deep forests used XGBoost as the estimator in the cascade, we applied LightGBM instead of XGBoost to the cascade forest as the estimator, then the estimator group was determined experimentally as three LightGBMs and three ExtraTrees, this new model is called LGBMDF. We conducted 5-fold cross-validation on LGBMDF and other state-of-the-art methods using the same dataset, and compared their Sn, Sp, MCC, AUC and AUPR. Finally, we found that our method has better performance and faster calculation speed.
Collapse
|
9
|
Lei S, Lei X, Liu L. Drug repositioning based on heterogeneous networks and variational graph autoencoders. Front Pharmacol 2022; 13:1056605. [PMID: 36618933 PMCID: PMC9812491 DOI: 10.3389/fphar.2022.1056605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Accepted: 12/13/2022] [Indexed: 12/24/2022] Open
Abstract
Predicting new therapeutic effects (drug repositioning) of existing drugs plays an important role in drug development. However, traditional wet experimental prediction methods are usually time-consuming and costly. The emergence of more and more artificial intelligence-based drug repositioning methods in the past 2 years has facilitated drug development. In this study we propose a drug repositioning method, VGAEDR, based on a heterogeneous network of multiple drug attributes and a variational graph autoencoder. First, a drug-disease heterogeneous network is established based on three drug attributes, disease semantic information, and known drug-disease associations. Second, low-dimensional feature representations for heterogeneous networks are learned through a variational graph autoencoder module and a multi-layer convolutional module. Finally, the feature representation is fed to a fully connected layer and a Softmax layer to predict new drug-disease associations. Comparative experiments with other baseline methods on three datasets demonstrate the excellent performance of VGAEDR. In the case study, we predicted the top 10 possible anti-COVID-19 drugs on the existing drug and disease data, and six of them were verified by other literatures.
Collapse
|
10
|
Hassam M, Bashir MA, Shafi S, Zahra NUA, Khan K, Jalal K, Siddiqui H, Uddin R. Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro. Comput Biol Med 2022; 151:106284. [PMID: 36370580 PMCID: PMC9635257 DOI: 10.1016/j.compbiomed.2022.106284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 10/13/2022] [Accepted: 10/30/2022] [Indexed: 11/06/2022]
Abstract
The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result of these VOCs, the fifth wave has already begun in several countries. The rapid spread of VOCs is posing a serious threat to human civilization. There is currently no specific medicine available for the treatment of COVID-19. Here, we present the findings of methods that used a combination of structure-assisted drug design, virtual screening, and high-throughput screening to swiftly generate lead compounds against Mpro protein of SARs-CoV-2. Therapeutics, in addition to vaccinations, are an essential element of the healthcare response to COVID-19's persistent threat. In the current study, we designed the efficient compounds that may combat all emerging variants of SARs-CoV-2 by targeting the common Mpro protein. The present study was aimed to discover new compounds that may be proposed as new therapeutic agents to treat COVID-19 infection without any adverse effects. For this purpose, a computational-based virtual screening of 352 in-house synthesized compounds library was performed through molecular docking and Molecular Dynamics (MD) simulation approach. As a result, four novel potent compounds were successfully shortlisted by implementing certain pharmacological, physiological, and ADMET criteria i.e., compounds 3, 4, 21, and 22. Furthermore, MD simulations were performed to evaluate the stability and dynamic behavior of these compounds with Mpro complex for about 30 ns. Eventually, compound 22 was found to be highly potent against Mpro protein and was further evaluated by applying 100 ns simulations. Our findings showed that these shortlisted compounds may have potency to treat the COVID-19 infection for which further experimental validation is proposed as part of a follow-up investigation.
Collapse
Affiliation(s)
- Muhammad Hassam
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan
| | - Muhammad Arslan Bashir
- Department of Avionics Engineering, College of Aeronautical Engineering, National University of Science and Technology, Risalpur, Pakistan
| | - Sarah Shafi
- HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan
| | - Noor-ul-Ain Zahra
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan,Institute of Organismic and Molecular Evolution, Faculty of Biology, Johannes Gutenberg Universität, 55128, Mainz, Germany
| | - Kanwal Khan
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan
| | - Khurshid Jalal
- HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan
| | - Hina Siddiqui
- HEJ Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan
| | - Reaz Uddin
- Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Pakistan,Corresponding author. Lab 103 PCMD ext. Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan
| |
Collapse
|
11
|
Kurata H, Tsukiyama S. ICAN: Interpretable cross-attention network for identifying drug and target protein interactions. PLoS One 2022; 17:e0276609. [PMID: 36279284 PMCID: PMC9591068 DOI: 10.1371/journal.pone.0276609] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 10/10/2022] [Indexed: 11/18/2022] Open
Abstract
Drug-target protein interaction (DTI) identification is fundamental for drug discovery and drug repositioning, because therapeutic drugs act on disease-causing proteins. However, the DTI identification process often requires expensive and time-consuming tasks, including biological experiments involving large numbers of candidate compounds. Thus, a variety of computation approaches have been developed. Of the many approaches available, chemo-genomics feature-based methods have attracted considerable attention. These methods compute the feature descriptors of drugs and proteins as the input data to train machine and deep learning models to enable accurate prediction of unknown DTIs. In addition, attention-based learning methods have been proposed to identify and interpret DTI mechanisms. However, improvements are needed for enhancing prediction performance and DTI mechanism elucidation. To address these problems, we developed an attention-based method designated the interpretable cross-attention network (ICAN), which predicts DTIs using the Simplified Molecular Input Line Entry System of drugs and amino acid sequences of target proteins. We optimized the attention mechanism architecture by exploring the cross-attention or self-attention, attention layer depth, and selection of the context matrixes from the attention mechanism. We found that a plain attention mechanism that decodes drug-related protein context features without any protein-related drug context features effectively achieved high performance. The ICAN outperformed state-of-the-art methods in several metrics on the DAVIS dataset and first revealed with statistical significance that some weighted sites in the cross-attention weight matrix represent experimental binding sites, thus demonstrating the high interpretability of the results. The program is freely available at https://github.com/kuratahiroyuki/ICAN.
Collapse
Affiliation(s)
- Hiroyuki Kurata
- Department of Bioscience and Bioinformatics, Kyushu Institute of Technology, Iizuka, Fukuoka, Japan
- * E-mail:
| | - Sho Tsukiyama
- Department of Bioscience and Bioinformatics, Kyushu Institute of Technology, Iizuka, Fukuoka, Japan
| |
Collapse
|
12
|
Kusuma WA, Habibi ZI, Amir MF, Fadli A, Khotimah H, Dewanto V, Heryanto R. Bipartite graph search optimization for type II diabetes mellitus Jamu formulation using branch and bound algorithm. Front Pharmacol 2022; 13:978741. [PMID: 36034833 PMCID: PMC9403330 DOI: 10.3389/fphar.2022.978741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Accepted: 07/14/2022] [Indexed: 11/26/2022] Open
Abstract
Jamu is an Indonesian traditional herbal medicine that has been practiced for generations. Jamu is made from various medicinal plants. Each plant has several compounds directly related to the target protein that are directly associated with a disease. A pharmacological graph can form relationships between plants, compounds, and target proteins. Research related to the prediction of Jamu formulas for some diseases has been carried out, but there are problems in finding combinations or compositions of Jamu formulas because of the increase in search space size. Some studies adopted the drug–target interaction (DTI) implemented using machine learning or deep learning to predict the DTI for discovering the Jamu formula. However, this approach raises important issues, such as imbalanced and high-dimensional dataset, overfitting, and the need for more procedures to trace compounds to their plants. This study proposes an alternative approach by implementing bipartite graph search optimization using the branch and bound algorithm to discover the combination or composition of Jamu formulas by optimizing the search on a plant–protein bipartite graph. The branch and bound technique is implemented using the search strategy of breadth first search (BrFS), Depth First Search, and Best First Search. To show the performance of the proposed method, we compared our method with a complete search algorithm, searching all nodes in the tree without pruning. In this study, we specialize in applying the proposed method to search for the Jamu formula for type II diabetes mellitus (T2DM). The result shows that the bipartite graph search with the branch and bound algorithm reduces computation time up to 40 times faster than the complete search strategy to search for a composition of plants. The binary branching strategy is the best choice, whereas the BrFS strategy is the best option in this research. In addition, the the proposed method can suggest the composition of one to four plants for the T2DM Jamu formula. For a combination of four plants, we obtain Angelica Sinensis, Citrus aurantium, Glycyrrhiza uralensis, and Mangifera indica. This approach is expected to be an alternative way to discover the Jamu formula more accurately.
Collapse
Affiliation(s)
- Wisnu Ananta Kusuma
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
- Tropical Biopharmaca Research Center, IPB University, Bogor, Indonesia
- *Correspondence: Wisnu Ananta Kusuma,
| | - Zulfahmi Ibnu Habibi
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| | - Muhammad Fahmi Amir
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| | - Aulia Fadli
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| | - Husnul Khotimah
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| | - Vektor Dewanto
- Department of Computer Science, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| | - Rudi Heryanto
- Tropical Biopharmaca Research Center, IPB University, Bogor, Indonesia
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, IPB University, Bogor, Indonesia
| |
Collapse
|
13
|
Matrix factorization with denoising autoencoders for prediction of drug–target interactions. Mol Divers 2022:10.1007/s11030-022-10492-8. [DOI: 10.1007/s11030-022-10492-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2022] [Accepted: 07/01/2022] [Indexed: 11/25/2022]
|
14
|
Mukaidaisi M, Vu A, Grantham K, Tchagang A, Li Y. Multi-Objective Drug Design Based on Graph-Fragment Molecular Representation and Deep Evolutionary Learning. Front Pharmacol 2022; 13:920747. [PMID: 35860028 PMCID: PMC9291509 DOI: 10.3389/fphar.2022.920747] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 05/26/2022] [Indexed: 11/19/2022] Open
Abstract
Drug discovery is a challenging process with a huge molecular space to be explored and numerous pharmacological properties to be appropriately considered. Among various drug design protocols, fragment-based drug design is an effective way of constraining the search space and better utilizing biologically active compounds. Motivated by fragment-based drug search for a given protein target and the emergence of artificial intelligence (AI) approaches in this field, this work advances the field of in silico drug design by (1) integrating a graph fragmentation-based deep generative model with a deep evolutionary learning process for large-scale multi-objective molecular optimization, and (2) applying protein-ligand binding affinity scores together with other desired physicochemical properties as objectives. Our experiments show that the proposed method can generate novel molecules with improved property values and binding affinities.
Collapse
Affiliation(s)
- Muhetaer Mukaidaisi
- Biomedical Data Science Laboratory, Department of Computer Science, Brock University, St. Catharines, ON, Canada
| | - Andrew Vu
- Biomedical Data Science Laboratory, Department of Computer Science, Brock University, St. Catharines, ON, Canada
| | - Karl Grantham
- Biomedical Data Science Laboratory, Department of Computer Science, Brock University, St. Catharines, ON, Canada
| | - Alain Tchagang
- Scientific Data Mining Team, Digital Technologies Research Centre, National Research Council Canada, Ottawa, ON, Canada
| | - Yifeng Li
- Biomedical Data Science Laboratory, Department of Computer Science, Brock University, St. Catharines, ON, Canada
- *Correspondence: Yifeng Li ,
| |
Collapse
|
15
|
Discovering driver nodes in chronic kidney disease-related networks using Trader as a newly developed algorithm. Comput Biol Med 2022; 148:105892. [DOI: 10.1016/j.compbiomed.2022.105892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 07/04/2022] [Accepted: 07/16/2022] [Indexed: 11/18/2022]
|
16
|
Shin SH, Oh SM, Yoon Park JH, Lee KW, Yang H. OptNCMiner: a deep learning approach for the discovery of natural compounds modulating disease-specific multi-targets. BMC Bioinformatics 2022; 23:218. [PMID: 35672685 PMCID: PMC9175487 DOI: 10.1186/s12859-022-04752-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Accepted: 05/25/2022] [Indexed: 11/22/2022] Open
Abstract
Background Due to their diverse bioactivity, natural product (NP)s have been developed as commercial products in the pharmaceutical, food and cosmetic sectors as natural compound (NC)s and in the form of extracts. Following administration, NCs typically interact with multiple target proteins to elicit their effects. Various machine learning models have been developed to predict multi-target modulating NCs with desired physiological effects. However, due to deficiencies with existing chemical-protein interaction datasets, which are mostly single-labeled and limited, the existing models struggle to predict new chemical-protein interactions. New techniques are needed to overcome these limitations. Results We propose a novel NC discovery model called OptNCMiner that offers various advantages. The model is trained via end-to-end learning with a feature extraction step implemented, and it predicts multi-target modulating NCs through multi-label learning. In addition, it offers a few-shot learning approach to predict NC-protein interactions using a small training dataset. OptNCMiner achieved better prediction performance in terms of recall than conventional classification models. It was tested for the prediction of NC-protein interactions using small datasets and for a use case scenario to identify multi-target modulating NCs for type 2 diabetes mellitus complications. Conclusions OptNCMiner identifies NCs that modulate multiple target proteins, which facilitates the discovery and the understanding of biological activity of novel NCs with desirable health benefits.
Supplementary Information The online version contains supplementary material available at 10.1186/s12859-022-04752-5.
Collapse
Affiliation(s)
- Seo Hyun Shin
- Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seung Man Oh
- Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jung Han Yoon Park
- Bio-MAX Institute, Seoul National University, Seoul, 08826, Republic of Korea
| | - Ki Won Lee
- Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea. .,Bio-MAX Institute, Seoul National University, Seoul, 08826, Republic of Korea. .,Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
| | - Hee Yang
- Bio-MAX Institute, Seoul National University, Seoul, 08826, Republic of Korea.
| |
Collapse
|
17
|
MacKinnon SS, Madani Tonekaboni SA, Windemuth A. Proteome-Scale Drug-Target Interaction Predictions: Approaches and Applications. Curr Protoc 2021; 1:e302. [PMID: 34794211 DOI: 10.1002/cpz1.302] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Drug-Target interaction predictions are an important cornerstone of computer-aided drug discovery. While predictive methods around individual targets have a long history, the application of proteome-scale models is relatively recent. In this overview, we will provide the context required to understand advances in this emerging field within computational drug discovery, evaluate emerging technologies for suitability to given tasks, and provide guidelines for the design and implementation of new drug-target interaction prediction models. We will discuss the validation approaches used, and propose a set of key criteria that should be applied to evaluate their validity. We note that we find widespread deficiencies in the existing literature, making it difficult to judge the practical effectiveness of some of the techniques proposed from their publications alone. We hope that this review may help remedy this situation and increase awareness of several sources of bias that may enter into commonly used cross-validation methods. © 2021 Cyclica Inc. Current Protocols published by Wiley Periodicals LLC.
Collapse
|